Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Miguel A. Varela

GROUP LEADER - DRUG DELIVERY

My research sits at the intersection of RNA biology, nucleic acid chemistry, and therapeutic development, with a focus on designing and delivering antisense-based medicines for conditions that currently lack effective treatments.

A key focus of my group is the delivery of nucleic acid therapeutics to tissues that remain difficult to reach, developing peptide- and antibody-conjugated systems that improve tissue uptake and selectivity. Some of this delivery work is progressing towards clinical translation.

Our work integrates chemistry, delivery science, and translational strategy, with the goal of building a platform that can be rapidly adapted across disease indications to deliver precision medicines to patients.